The British government should not get complacent about AstraZeneca’s U.S. listing, as it paves the way for a full one in New York.
CNBC’s UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
The British government should not get complacent about AstraZeneca’s U.S. listing, as it paves the way for a full one in New York.
